false
0002030617
0002030617
2026-03-13
2026-03-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 13, 2026
Picard Medical, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-42801 |
|
86-3212894 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
1992 E Silverlake
Tucson AZ, 85713 |
| (Address of principal executive offices, including zip code) |
Registrant’s telephone number, including
area code: (520) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
PMI |
|
The NYSE American, LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01. |
Regulation FD Disclosure. |
On March 13, 2026, Picard
Medical, Inc. (the “Company”) issued a press release announcing that the Company will be featured on BTV – Business
Television, with the segment scheduled to air on FOX Business News on March 14, 2026 at 5:00 p.m. Eastern Time. The segment will highlight
the SynCardia Total Artificial Heart (“TAH”) and the Company’s ongoing development of the next artificial heart technology.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
The
information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation
language in such filing.
| Item 9.01. |
Financial Statements and Exhibits. |
The following exhibits are
being furnished herewith:
| Exhibit No. |
|
Description |
| 99.1 |
|
Picard Medical, Inc. Press Release dated March 13, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Picard Medical, Inc. |
|
| |
|
| By: |
/s/ Patrick NJ Schnegelsberg |
|
| |
Name: |
Patrick NJ Schnegelsberg |
|
| |
Title: |
Chief Executive Officer |
|
Dated: March 13, 2026
Exhibit 99.1
Picard Medical / SynCardia Highlight Total Artificial Heart
on BTV Program Airing on FOX Business News
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced
heart failure and next-generation development programs
TUCSON, Ariz., March 13, 2026 —
Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the
world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total
Artificial Heart (“STAH”) will be featured in an upcoming segment on BTV Business Television airing on the FOX Business
News on Saturday, March 14 at 5:00 p.m. EST.
The segment will highlight the Company artificial heart technology designed to replace the pumping function of a failing human heart during the time that a patient awaits transplantation.
With more than 2,100 implants performed worldwide, the STAH remains the most widely used and extensively studied artificial heart technology globally. The device is considered a “total” replacement since it replaces both left and right ventricles and all four heart valves, restoring circulation in patients with severe biventricular heart failure who are at risk of imminent death without mechanical circulatory support.
The segment will also highlight the Company’s development of a next-generation, fully implantable artificial heart platform designed to improve patient mobility and quality of life by eliminating external pneumatic drivers.
“We believe raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechanical circulatory support continues to grow,” said Patrick N.J. Schnegelsberg, Chief Executive Officer of Picard Medical. “The SynCardia Total Artificial Heart has supported more than 2,100 patients worldwide by replacing the pumping function of a failing heart and providing critical time for patients awaiting transplantation. We are also advancing the next generation of artificial heart technology designed to further improve patient mobility and quality of life.”
BTV – Business Television is a long running investment focused television program that profiles emerging companies and technologies across a range of industries. The program airs across major financial networks and digital platforms and provides companies with exposure to retail and institutional investor audiences.
The Picard Medical segment will also be available via replay through BTV’s online distribution channels following the broadcast: http://www.b-tv.com/post/picard-medical-advancing-total-artificial-heart-technology-btv-feature.
About BTV – Business Television / BTV The Agency
For 28 years, BTV – Business Television has been on the air as the go-to half-hour investment show for savvy investors, delivering exclusive on-location interviews and actionable insights with emerging companies, industry leaders, and market experts. Hosted by Taylor Thoen and Jessica Katrichak, BTV provides investors with direct access to executive teams and compelling investment opportunities not found anywhere else. BTV The Agency is a capital markets–focused B2B TV production and digital marketing agency serving publicly traded and financial companies. Through strategic content creation and extensive distribution across top-tier networks including Bloomberg, CNBC, FOX Business News, and leading financial platforms, the agency helps companies reach investors, advisors, and institutions—building brand credibility and driving national retail and institutional investor awareness.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
